These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30268765)

  • 1. Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.
    Vranic S; Palazzo J; Sanati S; Florento E; Contreras E; Xiu J; Swensen J; Gatalica Z
    Clin Breast Cancer; 2019 Apr; 19(2):131-136. PubMed ID: 30268765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix.
    Cimic A; Vranic S; Arguello D; Contreras E; Gatalica Z; Swensen J
    Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):299-304. PubMed ID: 33208671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Profiling of the Metaplastic Spindle Cell Carcinoma of the Breast Reveals Potentially Targetable Biomarkers.
    Vranic S; Stafford P; Palazzo J; Skenderi F; Swensen J; Xiu J; Spetzler D; Gatalica Z
    Clin Breast Cancer; 2020 Aug; 20(4):326-331.e1. PubMed ID: 32197944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas.
    Koh J; Nam SK; Kwak Y; Kim G; Kim KK; Lee BC; Ahn SH; Park DJ; Kim HH; Park KU; Kim WH; Lee HS
    J Pathol; 2021 Jan; 253(1):94-105. PubMed ID: 32985687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic alterations of GI-NECs involving three main signaling pathways.
    Dai Q; Zhang J; Long W; Haybaeck J; Yang Z
    Cancer Med; 2023 Apr; 12(7):8238-8250. PubMed ID: 36653904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Characterization of Neuroendocrine Carcinomas of the Endometrium: Representation in All 4 TCGA Groups.
    Howitt BE; Dong F; Vivero M; Shah V; Lindeman N; Schoolmeester JK; Baltay M; MacConaill L; Sholl LM; Nucci MR; McCluggage WG
    Am J Surg Pathol; 2020 Nov; 44(11):1541-1548. PubMed ID: 32773531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and Immunohistochemical Studies Investigating the Histogenesis of Neuroendocrine and Carcinomatous Components of Combined Neuroendocrine Carcinoma.
    Iijima M; Yokobori T; Mogi A; Shimizu K; Yajima T; Kosaka T; Ohtaki Y; Obayashi K; Nakazawa S; Gombodorj N; Tsukagoshi M; Shirabe K; Kuwano H
    Ann Surg Oncol; 2019 Jun; 26(6):1744-1750. PubMed ID: 30924018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity.
    Sahnane N; Furlan D; Monti M; Romualdi C; Vanoli A; Vicari E; Solcia E; Capella C; Sessa F; La Rosa S
    Endocr Relat Cancer; 2015 Feb; 22(1):35-45. PubMed ID: 25465415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy.
    Roberts JA; Gonzalez RS; Das S; Berlin J; Shi C
    Hum Pathol; 2017 Dec; 70():49-54. PubMed ID: 29037958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are we ready to use TMB in breast cancer clinical practice?
    Ravaioli S; Limarzi F; Tumedei MM; Palleschi M; Maltoni R; Bravaccini S
    Cancer Immunol Immunother; 2020 Oct; 69(10):1943-1945. PubMed ID: 32725361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines.
    Krieg A; Mersch S; Boeck I; Dizdar L; Weihe E; Hilal Z; Krausch M; Möhlendick B; Topp SA; Piekorz RP; Huckenbeck W; Stoecklein NH; Anlauf M; Knoefel WT
    PLoS One; 2014; 9(2):e88713. PubMed ID: 24551139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neuroendocrine carcinoma of breast: a study of tumor morphology and subtyping].
    Gao LX; Liu G; Li L; Lin HY; Jin H; Cheng J; Jin ML; Ding HY
    Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):604-9. PubMed ID: 22177244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
    Gatalica Z; Xiu J; Swensen J; Vranic S
    Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olfactory receptor 51E1 protein as a potential novel tissue biomarker for small intestine neuroendocrine carcinomas.
    Cui T; Tsolakis AV; Li SC; Cunningham JL; Lind T; Öberg K; Giandomenico V
    Eur J Endocrinol; 2013 Feb; 168(2):253-61. PubMed ID: 23184910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
    Dill EA; Gru AA; Atkins KA; Friedman LA; Moore ME; Bullock TN; Cross JV; Dillon PM; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):334-342. PubMed ID: 28195880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets.
    Ang D; Ballard M; Beadling C; Warrick A; Schilling A; O'Gara R; Pukay M; Neff TL; West RB; Corless CL; Troxell ML
    Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):97-103. PubMed ID: 25679062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.
    Chamberlin MD; Bernhardt EB; Miller TW
    J Cell Biochem; 2016 Nov; 117(11):2454-63. PubMed ID: 27146558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.